Nautilus Biotechnology, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nautilus Biotechnology, Inc. (Nasdaq: NAUT) on November 3, 2025. The report addresses a regulatory event concerning the Company's listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on listing compliance status rather than financial performance.
Material Changes
The Company received written notice from Nasdaq Listing Qualifications staff confirming it has regained compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This compliance was achieved as the closing bid price of the Company's common stock met or exceeded $1.00 per share for a minimum of ten consecutive business days. Consequently, the matter regarding the minimum bid price requirement is now closed.
Outlook, Risks, and Management Commentary
Background: The Company previously received a deficiency notice on May 2, 2025, for failing to meet the $1.00 minimum bid price requirement on the Nasdaq Global Select Market. It was granted an initial 180-day compliance period ending October 28, 2025.
Market Transfer: On October 29, 2025, the Company transferred to The Nasdaq Capital Market. Under this transfer, the Company was afforded the remainder of the second 180-day compliance period, extending until April 27, 2026, to maintain compliance.
Current Status: The Company has successfully resolved the immediate compliance issue as of the report date.
Investor Verification Checklist
- Verify the current trading price of NAUT to ensure it remains above the $1.00 threshold.
- Confirm the Company's continued listing status on The Nasdaq Capital Market.
- Review the Company's most recent 10-Q or 10-K for financial metrics not included in this 8-K.
- Monitor future filings for any new notices regarding listing compliance or market transfers.